We support leading research projects in key research institutes and organisations across Australia.
Using the state-of-the-art robotic drug screening facility at Children’s Cancer Institute this study is designed to generate the evidence required to support a clinical trial for the most effective treatment combination for aggressiv neuroblastoma.. Read more
Dr Alla Dolnikov and her team at Children’s Cancer Institute have identified a drug that acts as an inhibitor to the MYC oncogene, opening up the potential of the immune cells to fight the tumour. Read more
This ground breaking project aims to identify the specific drivers of TERT oncogene rearrangement in high-risk neuroblastoma and demonstrate novel therapies that specifically target these drivers. Read more
Two projects from the Children's Cancer Institute were considered to be outstanding by the Neuroblastoma Australia Scientific Advisory Board and have been recommended for grants of $125,000 each for 2020. Read more
We currently support a range of promising research projects at the CCI including CBL137 single agent clinical trials. Find out more about the incredible work currently being undertaken. Read more
Find out about our partnership with the Sydney Children's Hospital and UNSW to gather information regarding the long term effects of childhood cancer treatments and how this data can be used to improve the long-term health of Australian childhood cancer survivors. Read more
With our support that Peter MacCallum Cancer Centre has pioneered the use of peptide receptor radionuclide therapy (PRRT) in neuroblastoma as an alternative therapy, especially in cases that have failed conventional treatment approaches. Read more